TITLE

Current Drug Therapy for Multiple Myeloma

AUTHOR(S)
Huang, Y-W.; Hamilton, A.; Arnuk, O.J.; Chaftari, P.; Chemaly, R.
PUB. DATE
April 1999
SOURCE
Drugs;Apr1999, Vol. 57 Issue 4, p485
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recent years have witnessed tremendous advances in the molecular pathogenesis and management of multiple myeloma. Standard chemotherapy (melphalan and prednisone; MP) has been the mainstay of treatment of multiple myeloma for about 3 decades. However, it is no longer considered the ‘gold standard’, particularly for those patients who will subsequently undergo intensive chemotherapy with autologous or allogeneic peripheral blood stem cell (PBSC) or bone marrow transplantation (BMT), or for patients with refractory myeloma. A variety of induction combination chemotherapy regimens have been developed, some of which have demonstrated an improved response rate and duration and a superior 5-year survival rate when compared with standard chemotherapy. The early use of high dose chemotherapy with autologous PBSC support or BMT has significantly increased the complete remission rate, and has prolonged event-free survival and overall survival. Allogeneic bone marrow or PBSC transplantation may be a good option for selected patients with poor prognostic features. The role of interferon-α in multiple myeloma is still inconclusive despite many years of clinical evaluation. The clinical application of chemosensitising agents that can inhibit P-glycoprotein (P-gp) expression and function, and particularly the development of more potent P-gp modulators such as valspodar (PSC 833) and elacridar (GF120918) has made it possible to reverse multidrug resistance in some refractory patients and to enhance the efficacy of chemotherapeutic agents. Immunotherapeutic approaches to purging of autologous bone marrow or PBSC, or as adjuvant therapy for minimal residual disease, show great promise. Finally, a number of new therapies specifically designed to treat many of the complications of multiple myeloma are improving clinical outcomes and quality of life for these patients.
ACCESSION #
9592820

 

Related Articles

  • The finger of the culprit. Schultz, Thomas F.; Weiss, Robin A. // Nature;1/5/1995, Vol. 373 Issue 6509, p17 

    Reports on Y. Chang et al.'s identification of a human herpes virus in Kaposi's sarcoma (KS). Epidemiologal indicators; Transmission; Prevalence; Role of the herpes virus in the development of KS.

  • Herpes Simplex Virus Type 2 Triggers Reactivation of Kaposi's Sarcoma-Associated Herpesvirus from Latency and Collaborates with HIV-1 Tat. Qiao Tang; Di Qin; Zhigang Lv; Xiaolei Zhu; Xinting Ma; Qin Yan; Yi Zeng; Yuanyuan Guo; Ninghan Feng; Chun Lu // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Kaposi's sarcoma-associated herpesvirus (KSHV) infection was necessary but not sufficient for Kaposi's sarcoma (KS) development without other cofactors. Previously, we identified that both human immunodeficiency type 1 (HIV-1) Tat and herpes simplex virus 1 (HSV-1) were important cofactors...

  • Kaposi's varcicelliform eruption. Shenoy, Manjunath M.; Suchitra, U. // Indian Journal of Dermatology, Venereology & Leprology;Jan/Feb2007, Vol. 73 Issue 1, p80 

    Kaposi's varicelliform eruption (eczema herpeticum) is the name given to a distinct cutaneous eruption caused by herpes simplex and certain other viruses that infect persons with preexisting dermatosis. Most commonly it is associated with atopic dermatitis. We report a case of a three-year-old...

  • Environmental Factors Influence the Rate of Human Herpesvirus Type 8 Infection in a Population with High Incidence of Classic Kaposi Sarcoma. Angeloni, Antonio; Masala, Maria Vittoria; Montesu, Maria Antonietta; Santarelli, Roberta; Satta, Rosanna; Ceccherini-Nelli, Luca; Valdivieso, Paola; Faggioni, Alberto; Cottoni, Francesca // Clinical Infectious Diseases;4/1/2006, Vol. 42 Issue 7, pE66 

    High prevalence of human herpesvirus type 8 (HHV-8) infection has been reported on the island of Sardinia. Among emigrants from Sardinia, rates of HHV-8 infection are lower than they are in Sardinia and are similar to those observed in the local population. Thus, environmental factors seem to...

  • Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's Sarcoma-associated herpesvirus by herpes simplex virus type 1.  // BMC Microbiology;2011, Vol. 11 Issue 1, p240 

    The article focuses on a study which identifies the significance of activation of PI3K/AKT and ERK MAPK signal pathways for the induction of lytic cycle replication of Kaposi's Sarcoma-associated herpesvirus. The study found that to regulate HSV-1-induced KSHV replication, either Janus kinase 1...

  • Herpes Simplex Virus Type 2 Triggers Reactivation of Kaposi's Sarcoma-Associated Herpesvirus from Latency and Collaborates with HIV-1 Tat. Qiao Tang; Di Qin; Zhigang Lv; Xiaolei Zhu; Xinting Ma; Qin Yan; Yi Zeng; Yuanyuan Guo; Ninghan Feng; Chun Lu // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Kaposi's sarcoma-associated herpesvirus (KSHV) infection was necessary but not sufficient for Kaposi's sarcoma (KS) development without other cofactors. Previously, we identified that both human immunodeficiency type 1 (HIV-1) Tat and herpes simplex virus 1 (HSV-1) were important cofactors...

  • Seroprevalence of Kaposi Sarcoma--associated Herpesvirus and Other Serologic Markers in the Brazilian Amazon. Nascimento, Maria C.; Sumita, Laura M.; Souza, Vanda U.; Weiss, Helen A.; Oliveira, Juliane; Mascheretti, Melissa; Quiroga, Mariana; Vela, Rodrigo A. R.; Sabino, Ester; Pannuti, Claudio S.; Mayaud, Philippe // Emerging Infectious Diseases;Apr2009, Vol. 15 Issue 4, p663 

    To determine the presence of Kaposi sarcoma--associated herpesvirus (KSHV) and other serologic markers, we tested serum specimens of 339 Amerindians, 181 rural non-Amerindians, and 1,133 urban blood donors (13 Amerindians) in the Brazilian Amazon. High KSHV seroprevalence in children and inverse...

  • Mini outbreak of Kaposi's varicelliform eruption in skin ward: A study of five cases. Rao, G. R. R.; Chalam, K. V.; Prasad, G. P.; Sarnathan, M.; Kumar, H. K. Y. // Indian Journal of Dermatology, Venereology & Leprology;Jan/Feb2007, Vol. 73 Issue 1, p33 

    Background: Kaposi`s varicelliform eruption (KVE) represents widespread cutaneous herpes simplex virus (HSV) infection in patients with preexisting dermatoses. Occasionally, this infection can present as a nosocomial infection in skin wards, if adequate bed-spacing and barrier nursing methods...

  • An unusual presentation of Castleman's Disease:a case report. Izuchukwu, Ifeoma S.; Tourbaf, Kamal; Mahoney, Martin C. // BMC Infectious Diseases;2003, Vol. 3 Issue 1, p20 

    Background: Castleman's disease (CD), a rare condition of uncertain etiology, involves a massive proliferation of lymphoid tissues and typically presents as mediastinal masses. We describe a patient with CD who presented with diffuse adenopathy involving the inguinal, paratracheal,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics